Literature DB >> 9029019

Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia.

L R Hiorns1, G J Swansbury, J Mehta, T Min, M G Dainton, J Treleaven, R L Powles, D Catovsky.   

Abstract

Acute promyelocytic leukaemia (APL) has been associated with a favourable prognosis in many studies of acute myeloid leukaemia. A series of 54 patients treated at the Royal Marsden Hospital between 1979 and 1996, with APL and the t(15;17) chromosome translocation at presentation, was examined for the effect of additional chromosome abnormalities in their presentation karyotype on survival. The patients were aged between 2 and 62 years with a median age of 31 years. There were approximately equal numbers of males and females. Presentation white cell count ranged from O.7 to 156 x 10(9)/l with a median of 1.0 x 10(9)/l. 39% of patients (21/54) had additional chromosome abnormalities at presentation. Statistical analyses were performed for factors thought to influence survival such as age, sex, white cell count, and number of courses of chemotherapy required to enter remission. These showed that the presence of additional chromosome abnormalities has an adverse effect on prognosis, independent of other prognostic indicators, reducing it to the level of patients with AML from less-favourable cytogenetic subgroups. These data indicate that additional therapeutic strategies may be required in patients with APL who demonstrate cytogenetic aberrations over and above the t(15;17) at presentation. The biological basis for the more aggressive nature of these cases remains to be determined.

Entities:  

Mesh:

Year:  1997        PMID: 9029019     DOI: 10.1046/j.1365-2141.1997.d01-2037.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

1.  Impairment of p53 acetylation, stability and function by an oncogenic transcription factor.

Authors:  Alessandra Insinga; Silvia Monestiroli; Simona Ronzoni; Roberta Carbone; Mark Pearson; Giancarlo Pruneri; Giuseppe Viale; Ettore Appella; PierGiuseppe Pelicci; Saverio Minucci
Journal:  EMBO J       Date:  2004-02-19       Impact factor: 11.598

2.  Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17).

Authors:  Peter H Wiernik; Zhuoxin Sun; Holly Gundacker; Gordon Dewald; Marilyn L Slovak; Elisabeth Paietta; Haesook T Kim; Frederick R Appelbaum; Peter A Cassileth; Martin S Tallman
Journal:  Med Oncol       Date:  2012-05-22       Impact factor: 3.064

3.  Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.

Authors:  Muhamed Baljevic; Bogdan Dumitriu; Ju-Whei Lee; Elisabeth M Paietta; Peter H Wiernik; Janis Racevskis; Christina Chen; Eytan M Stein; Robert E Gallagher; Jacob M Rowe; Frederick R Appelbaum; Bayard L Powell; Richard A Larson; Steven E Coutré; Jeffrey Lancet; Mark R Litzow; Selina M Luger; Neal S Young; Martin S Tallman
Journal:  Acta Haematol       Date:  2016-09-16       Impact factor: 2.195

Review 4.  Global characteristics of childhood acute promyelocytic leukemia.

Authors:  L Zhang; A Samad; M S Pombo-de-Oliveira; G Scelo; M T Smith; J Feusner; J L Wiemels; C Metayer
Journal:  Blood Rev       Date:  2014-09-30       Impact factor: 8.250

5.  Effect of additional chromosomal abnormalities in acute promyelocytic leukemia treated with all-trans-retinoic acid: a report of 17 patients.

Authors:  Y Okoshi; H Akiyama; N Kono; T Matsumura; D Mizuchi; S Mori; K Ohashi; H Sakamaki
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

6.  Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence.

Authors:  M Pantic; A Novak; D Marisavljevic; V Djordjevic; I Elezovic; A Vidovic; M Colovic
Journal:  Med Oncol       Date:  2000-11       Impact factor: 3.064

Review 7.  Cytogenetics in acute myeloid leukemia.

Authors:  Claudia Schoch; Torsten Haferlach
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

Review 8.  Management of acute promyelocytic leukemia.

Authors:  Martin S Tallman; Chadi Nabhan
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

9.  Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

Authors:  José Cervera; Pau Montesinos; Jesús M Hernández-Rivas; María J Calasanz; Anna Aventín; María T Ferro; Elisa Luño; Javier Sánchez; Edo Vellenga; Chelo Rayón; Gustavo Milone; Javier de la Serna; Concha Rivas; José D González; Mar Tormo; Elena Amutio; Marcos González; Salut Brunet; Bob Lowenberg; Miguel A Sanz
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

10.  High expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) is associated with poor prognosis in acute myeloid leukemia.

Authors:  Ling-Yu Zhou; Jia-Yu Yin; Qin Tang; Ling-Ling Zhai; Tin-Juan Zhang; Yu-Xin Wang; Dong-Qin Yang; Jun Qian; Jiang Lin; Zhao-Qun Deng
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.